Effector Common Stock Shares Outstanding vs Cash And Short Term Investments Analysis
EFTR Stock | USD 1.79 0.08 4.28% |
Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Common Stock Shares Outstanding and its Cash And Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.
Common Stock Shares Outstanding vs Cash And Short Term Investments
Common Stock Shares Outstanding vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Common Stock Shares Outstanding account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Effector Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments is 0.77. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Effector Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Common Stock Shares Outstanding i.e., Effector Therapeutics' Common Stock Shares Outstanding and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.77 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Effector Therapeutics balance sheet. This account contains Effector Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Effector Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 05/22/2024, Sales General And Administrative To Revenue is likely to grow to 3.47, while Selling General Administrative is likely to drop slightly above 10.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 31.9M | 32.4M | 33.7M | 33.6M | Cost Of Revenue | 24K | 53K | 111K | 105.5K |
Effector Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Effector Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.